SeaStar Medical Holding CorpICU

NasdaqHealthcareSurgical & Medical Instruments & Apparatus
Price (close)
$3.44
Market cap
$15.2M
P/E
—
Revenue (TTM)
$1.7M
Net income
-$13.6M
Dividend yield
—
1-year total return
-43.4%
Net margin
-795.5%
Revenue growth
123.6%
Debt / equity
0.00x

What SeaStar Medical Holding Corp does.

Unless the context otherwise requires, all references in this section to “SeaStar Medical”, the “Company”, “we” “us” or “our” refer to SeaStar Medical Holding Corporation and our consolidated subsidiaries following the Business Combination (as defined herein), other than certain historical information that refers to the business of SeaStar Medical, Inc. (the “Predecessor”) prior to the consummation of the Business Combination.

We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.

We received Food and Drug Administration (“FDA”) approval on February 21, 2024, under a Humanitarian Device Exemption (“HDE”) for our pediatric SCD therapy. It is the only FDA approved product for use in pediatric patients with acute kidney injury (“AKI”) due to sepsis or a septic condition requiring kidney replacement therapy. We shipped our first commercial pediatric SCD (“QUELIMMUNE”) in July 2024. In addition, we are currently conducting a pivotal clinical trial, also referred to as "NEUTRALIZE-AKI" to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy (“CRRT”). We are also conducting a feasibility study of the SCD therapy in adult patients with Cardiorenal Syndrome ("CRS") awaiting left ventricular assist device ("LVAD") implantation.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue———$0$135,000$1.2M
Net income—-$4.6M-$12.2M-$26.2M-$24.8M-$12.2M

More on ICU.

Figures from SeaStar Medical Holding Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.